Healio

Infliximab bests cyclophosphamide as first-line treatment of severe Behçet’s syndrome

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...
MarketWatch

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...
Morningstar

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Medscape

British Societies Develop First 'Living' Behçet Guidelines

LIVERPOOL, ENGLAND — The British Society for Rheumatology (BSR) and the British Association of Dermatologists (BAD) have joined forces for the first time to develop the first British guidelines for ...

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
Nasdaq

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Healio

Adalimumab slashes Behçet’s uveitis relapse rate significantly more than cyclosporine

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...
Medscape

Biomarkers in Behçet's Disease: Diagnosis and Disease Activity

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...
Nasdaq

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
The New England Journal of Medicine

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

Methods We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behçet’s syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast ...
Seeking Alpha

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy The Phase 2a study, evaluating control of oral ...